AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco
US drugmakers AMAG Pharmaceuticals (Nasdaq: AMAG) and Allos Therapeutics (Nasdaq: ALTH) entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of around $686 million.
The news saw AMAG’s shares plunge 14% to $16.46, while Allos dipped 1%, with Adam Feurstein writing in The Street, saying this “might be the nuttiest, most nonsensical business combination in biotech history.” The only thing AMAG and Allos have in common is that they have largely failed initial efforts to sell their respective drugs, neither of which have anything to do with each other, he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze